Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors.
about
DNA repair targeted therapy: The past or future of cancer treatment?Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewPolypharmacology in Precision Oncology: Current Applications and Future ProspectsSublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells.PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant gliomaNon-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivoNCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative NeoplasmsObjective, Quantitative, Data-Driven Assessment of Chemical Probes.ECBS & ICBS 2015 Joint Meeting: Bringing Chemistry to Life.PARP inhibitors: Clinical utility and possibilities of overcoming resistance.PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS.Dual Inhibitors of PARPs and ROCKsHomologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
P2860
Q26768679-7B154DD8-A832-40D9-A1A1-1F12CE8B0CBEQ27304386-E45C3CA1-8C12-40C1-927F-3DE785001410Q30846907-3E493BB1-35A6-4560-BF40-6042305961A4Q33757073-FED86115-AD52-4B7B-AC40-4D850323F622Q35741555-A10042B0-5CEB-4B21-B7C3-E59E7817AAF6Q36160278-F3755D7A-2834-4571-9DBD-839F2063B595Q37590339-33F81A47-F7E0-4444-A56D-EB22CB98A45DQ38596368-00E53A9A-10F7-492A-9ADF-D01B8AF02D19Q38954348-4A085526-B6FB-4844-9442-00DC33ED2ACEQ40465701-2A38B207-8C2F-49CF-9DEE-DECB4307CF00Q41217822-30E530A9-0C67-4D7A-B779-39EBA545F484Q47294977-9AB5BF77-A935-46E6-80CD-188F1E5973B3Q48893627-9E8E742D-6985-4747-9E82-74F10091A2B4Q50076626-469FE514-42C7-4A28-8031-A40FB7A571B5Q50980480-98263879-690B-4324-9FAF-0807EB0C678FQ58581240-78F6CE9A-3373-4268-8BEB-9CB8AAE94761Q58801181-C93DEE1C-88DE-4886-A1D1-B21A482E449B
P2860
Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Linking off-target kinase phar ...... bserved among PARP inhibitors.
@en
Linking off-target kinase phar ...... bserved among PARP inhibitors.
@nl
type
label
Linking off-target kinase phar ...... bserved among PARP inhibitors.
@en
Linking off-target kinase phar ...... bserved among PARP inhibitors.
@nl
prefLabel
Linking off-target kinase phar ...... bserved among PARP inhibitors.
@en
Linking off-target kinase phar ...... bserved among PARP inhibitors.
@nl
P2860
P356
P1433
P1476
Linking off-target kinase phar ...... observed among PARP inhibitors
@en
P2093
Jordi Mestres
P2860
P304
P356
10.18632/ONCOTARGET.1814
P407
P577
2014-05-01T00:00:00Z